ClinicalTrials.gg
CompletedNCT03675477Updated Jun 2, 2023Results posted

A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis.

A Phase 2 interventional study of SHR0302 and Placebo in Ulcerative Colitis, sponsored by Reistone Biopharma Company Limited. Completed at 67 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-06-02.

Sponsored by Reistone Biopharma Company Limited (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
164
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 183 studies in Colitis, Ulcerative with a site in China — 72 open to participants now, 95 under way, 25 of them phase 3. Colitis, Ulcerative · China.

Enrollment
57th of 135
164 · median 120
Started
2019
with 12 others
Phase 2
34 of 183
14 open now
Registered
38th of 183
by date

Among the 183 studies in Colitis, Ulcerative with a site in China, this one is the 57th largest by enrollment of the 135 interventional ones that give a count, is one of 13 that started in 2019, is one of 34 in phase 2, and was the 38th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

72 of the 183 studies in Colitis, Ulcerative with a site in China are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 183 studies in Colitis, Ulcerative with a site in China, or all of them as a file.
02

Study summary

The proposed study is a randomized, double-blind,placebo-controlled, multicenter phase II study to investigate the safety and efficacy of SHR0302 in patients with moderate to severe active ulcerative colitis. The study aims to evaluate the optimal dose of SHR0302 and time needed to induce clinical response in active ulcerative colitis patients.

This is an 8+8 weeks study, in which participants who complete the first 8 weeks treatment phase, will have the option to enter a blinded active arms 8-week extension phase. Early withdrawn subjects during the first treatment phase can not enter the extension phase. The total duration of the study participation, including extension and follow-up, will be approximately 18 weeks.

SHR0302 is a Janus kinase 1(JAK1) inhibitor, capable of blocking Janus kinase-signal transducer and activator of transcription (JAK-STATs) pathway and controlling inflammation. Therefore it has the potential to be a treatment for ulcerative colitis.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and Female subject age ≥ 18 and ≤75 years of age at randomization.
  • Active ulcerative colitis with a 9-point modified Mayo score of 5 to 9 points and endoscopic subscore of 2 to 3 (The duration of the time between endoscopy and baseline should not exceed 10 days and allow central over read turn over before randomization).
  • Subject should have at least three-month history of Ulcerative Colitis diagnosis at randomization.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of indeterminate colitis, or clinical findings suggestive of Crohn's disease.
  • Subjects with ulcerative colitis, which is confined to a proctitis (distal 15 cm or less).
  • Treatment naïve subjects diagnosed with ulcerative colitis (without previous exposure to treatment).
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
164 participants (actual)

Study arms

  • Experimental
    SHR0302 8mg QD

    Participants randomized in this arm will receive SHR0302 8mg QD for the treatment phase. All participants that had completed the 8-week treatment phase (non-responders or responders) had the option to enter a blinded 8-week extension phase to continue to receive SHR0302 8mg QD. Those who had completed the first 8-week of the treatment phase, but decided not to enter into the extension phase were also required to attend the 2-week follow-up visit. Participants who immaturely withdrew during the first treatment phase could not enter the extension phase. SHR0302: The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a JAK inhibitor).

    Drug: SHR0302

  • Experimental
    SHR0302 4mg BD

    Participants randomized in this arm will receive SHR0302 4mg BD for the treatment phase. All participants that had completed the 8-week treatment phase (non-responders or responders) had the option to enter a blinded 8-week extension phase to continue to receive SHR0302 4mg BD. Those who had completed the first 8-week of the treatment phase, but decided not to enter into the extension phase were also required to attend the 2-week follow-up visit. Participants who immaturely withdrew during the first treatment phase could not enter the extension phase. SHR0302: The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a JAK inhibitor).

    Drug: SHR0302

  • Experimental
    SHR0302 4mg QD

    Participants randomized in this arm will receive SHR0302 4mg QD for the treatment phase. All participants that had completed the 8-week treatment phase (non-responders or responders) had the option to enter a blinded 8-week extension phase to continue to receive SHR0302 4mg QD. Those who had completed the first 8-week of the treatment phase, but decided not to enter into the extension phase were also required to attend the 2-week follow-up visit. Participants who immaturely withdrew during the first treatment phase could not enter the extension phase. SHR0302: The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a JAK inhibitor).

    Drug: SHR0302

  • Placebo comparator
    placebo

    Participants randomized in this arm will receive the placebo until week 8, and then will be re-randomized into one of the 3 active arms ( 4mg QD, 4mg BD, 8mg QD of SHR0302) in a 1:1:1 allocation ratio until the end of the study at week 16. Those who had completed the first 8-week of the treatment phase, but decided not to enter into the extension phase were also required to attend the 2-week follow-up visit. Participants who immaturely withdrew during the first treatment phase could not enter the extension phase. SHR0302: The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a JAK inhibitor). Placebos: Placebo Oral Tablet

    Drug: SHR0302 · Drug: Placebo

Interventions

  • The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a Janus kinase inhibitor).

    Also known as: Ivarmacitinib

  • DrugPlacebo

    Placebo Oral Tablet

06

What researchers measure

Primary outcomes

  1. The Percentage of Subject Achieve Clinical Response at Week 8

    Clinical response is defined as a decrease from baseline in a 9-point modified Mayo score of at least 2 points and at least 30%, with an accompanying reduction in the subscore for rectal bleeding of at least 1 point or absolute subscore for rectal bleeding of 0 or 1. The 9-point modified Mayo score is the Mayo score excluding the Physician Global Assessment sub-score, hence the maximum is 9 points and the minimum is 0 point, includes: Stool Frequency 0 = Normal 1. = 1-2 stools/day more than normal 2. = 3-4 stools/day more than normal 3. = 5 or more stools/day than normal Rectal bleeding 0 = None 1. = Visible blood with stool less than half the time 2. = Visible blood with stool half of the time or more 3. = Passing blood alone Mucosal appearance at endoscopy 0 = Normal or inactive disease 1. = Mild disease (erythema, decreased vascular pattern, mild friability 2. = Moderate disease (marked erythema, absent vascular pattern, friability, erosio

    Time frame: Week 8

Secondary outcomes

  1. The Percentage of Subjects Achieve Clinical Remission

    Clinical remission was defined as a total Mayo score of 2 points or lower, with no individual sub-score exceeding 1 point. The percentage of subjects who achieve clinical remission per 9-point modified Mayo score at week 8, where stool frequency subscore ≤ 1, rectal bleeding subscore of 0, and endoscopic subscore ≤ 1. 9-point modified Mayo score includes: Stool Frequency 0 = Normal 1. = 1-2 stools/day more than normal 2. = 3-4 stools/day more than normal 3. = 5 or more stools/day than normal Rectal bleeding 0 = None 1. = Visible blood with stool less than half the time 2. = Visible blood with stool half of the time or more 3. = Passing blood alone Mucosal appearance at endoscopy 0 = Normal or inactive disease 1. = Mild disease (erythema, decreased vascular pattern, mild friability 2. = Moderate disease (marked erythema, absent vascular pattern, friability, erosions) 3. = Severe disease (spontaneous bleeding, ulceration)

    Time frame: Week 8

  2. The Percentage of Subjects Achieve Clinical Remission at Week 8

    Clinical remission was defined as a total Mayo score of 2 points or lower, with no individual sub-score exceeding 1 point. The percentage of subjects achieve clinical remission at week 8 as per a total Mayo score of 2 points or lower ≤2, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. The 9-point modified Mayo score includes: Stool Frequency 0 = Normal 1. = 1-2 stools/day more than normal 2. = 3-4 stools/day more than normal 3. = 5 or more stools/day than normal Rectal bleeding 0 = None 1. = Visible blood with stool less than half the time 2. = Visible blood with stool half of the time or more 3. = Passing blood alone Mucosal appearance at endoscopy 0 = Normal or inactive disease 1. = Mild disease (erythema, decreased vascular pattern, mild friability 2. = Moderate disease (marked erythema, absent vascular patt

    Time frame: Week 8

  3. The Percentage of Subjects Achieve Endoscopic Remission (Mucosal Healing) at Week 8

    Endoscopic remission was defined by Mayo endoscopic subscore ≤ 1 point. Mayo endoscopic subscore defines score 0 as normal or inactive disease, score 1 as mild disease (erythema, decreased vascular pattern, mild friability); score 2 as moderate disease (marked erythema, absent vascular pattern, friability, erosions); score 3 as severe disease (spontaneous bleeding, ulceration).

    Time frame: Week 8

07

Results

Posted Nov 22, 2022

Participant flow

Treatment Phase
Participant flow — Treatment Phase
MilestoneSHR0302 8mg QDSHR0302 4mg BDSHR0302 4mg QDPlacebo
Started41414141
Completed41414141
Not completed0000
Extension Phase
Participant flow — Extension Phase
MilestoneSHR0302 8mg QDSHR0302 4mg BDSHR0302 4mg QDPlacebo
Started4749480
Completed4749480
Not completed0000

Outcome measures

PrimaryThe Percentage of Subject Achieve Clinical Response at Week 8

Clinical response is defined as a decrease from baseline in a 9-point modified Mayo score of at least 2 points and at least 30%, with an accompanying reduction in the subscore for rectal bleeding of at least 1 point or absolute subscore for rectal bleeding of 0 or 1. The 9-point modified Mayo score is the Mayo score excluding the Physician Global Assessment sub-score, hence the maximum is 9 points and the minimum is 0 point, includes: Stool Frequency 0 = Normal 1. = 1-2 stools/day more than normal 2. = 3-4 stools/day more than normal 3. = 5 or more stools/day than normal Rectal bleeding 0 = None 1. = Visible blood with stool less than half the time 2. = Visible blood with stool half of the time or more 3. = Passing blood alone Mucosal appearance at endoscopy 0 = Normal or inactive disease 1. = Mild disease (erythema, decreased vascular pattern, mild friability 2. = Moderate disease (marked erythema, absent vascular pattern, friability, erosio

Time frame:
Week 8
Reported as:
Number · percentage of participants
The Percentage of Subject Achieve Clinical Response at Week 8
percentage of participantsSHR0302 8mg QDSHR0302 4mg BDSHR0302 4mg QDPlacebo
The Percentage of Subject Achieve Clinical Response at Week 846.346.343.926.8
SecondaryThe Percentage of Subjects Achieve Clinical Remission

Clinical remission was defined as a total Mayo score of 2 points or lower, with no individual sub-score exceeding 1 point. The percentage of subjects who achieve clinical remission per 9-point modified Mayo score at week 8, where stool frequency subscore ≤ 1, rectal bleeding subscore of 0, and endoscopic subscore ≤ 1. 9-point modified Mayo score includes: Stool Frequency 0 = Normal 1. = 1-2 stools/day more than normal 2. = 3-4 stools/day more than normal 3. = 5 or more stools/day than normal Rectal bleeding 0 = None 1. = Visible blood with stool less than half the time 2. = Visible blood with stool half of the time or more 3. = Passing blood alone Mucosal appearance at endoscopy 0 = Normal or inactive disease 1. = Mild disease (erythema, decreased vascular pattern, mild friability 2. = Moderate disease (marked erythema, absent vascular pattern, friability, erosions) 3. = Severe disease (spontaneous bleeding, ulceration)

Time frame:
Week 8
Reported as:
Number · percentage of participants
The Percentage of Subjects Achieve Clinical Remission
percentage of participantsSHR0302 8mg QDSHR0302 4mg BDSHR0302 4mg QDPlacebo
The Percentage of Subjects Achieve Clinical Remission22.024.424.44.9
SecondaryThe Percentage of Subjects Achieve Clinical Remission at Week 8

Clinical remission was defined as a total Mayo score of 2 points or lower, with no individual sub-score exceeding 1 point. The percentage of subjects achieve clinical remission at week 8 as per a total Mayo score of 2 points or lower ≤2, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. The 9-point modified Mayo score includes: Stool Frequency 0 = Normal 1. = 1-2 stools/day more than normal 2. = 3-4 stools/day more than normal 3. = 5 or more stools/day than normal Rectal bleeding 0 = None 1. = Visible blood with stool less than half the time 2. = Visible blood with stool half of the time or more 3. = Passing blood alone Mucosal appearance at endoscopy 0 = Normal or inactive disease 1. = Mild disease (erythema, decreased vascular pattern, mild friability 2. = Moderate disease (marked erythema, absent vascular patt

Time frame:
Week 8
Reported as:
Number · percentage of participants
The Percentage of Subjects Achieve Clinical Remission at Week 8
percentage of participantsSHR0302 8mg QDSHR0302 4mg BDSHR0302 4mg QDPlacebo
The Percentage of Subjects Achieve Clinical Remission at Week 814.617.117.12.4
SecondaryThe Percentage of Subjects Achieve Endoscopic Remission (Mucosal Healing) at Week 8

Endoscopic remission was defined by Mayo endoscopic subscore ≤ 1 point. Mayo endoscopic subscore defines score 0 as normal or inactive disease, score 1 as mild disease (erythema, decreased vascular pattern, mild friability); score 2 as moderate disease (marked erythema, absent vascular pattern, friability, erosions); score 3 as severe disease (spontaneous bleeding, ulceration).

Time frame:
Week 8
Reported as:
Number · percentage of participants
The Percentage of Subjects Achieve Endoscopic Remission (Mucosal Healing) at Week 8
percentage of participantsSHR0302 8mg QDSHR0302 4mg BDSHR0302 4mg QDPlacebo
The Percentage of Subjects Achieve Endoscopic Remission (Mucosal Healing) at Week 826.829.336.614.6

Adverse events

Collected over 18 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Phase-SHR0302 8mg QD0/41 (0%)2/41 (4.9%)13/41 (31.7%)
Treatment Phase-SHR0302 4mg BD0/41 (0%)0/41 (0%)11/41 (26.8%)
Treatment Phase-SHR0302 4mg QD0/41 (0%)2/41 (4.9%)12/41 (29.3%)
Treatment Phase-Placebo0/41 (0%)2/41 (4.9%)7/41 (17.1%)
Extension Phase-SHR0302 8mg QD → SHR0302 8mg QD0/36 (0%)1/36 (2.8%)13/36 (36.1%)
Extension Phase-SHR0302 4mg BD → SHR0302 4mg BD0/39 (0%)0/39 (0%)8/39 (20.5%)
Extension Phase-SHR0302 4mg QD → SHR0302 4mg QD0/35 (0%)0/35 (0%)11/35 (31.4%)
Extension Phase-placebo → SHR0302 8mg QD0/11 (0%)1/11 (9.1%)5/11 (45.5%)
Extension Phase-placebo → SHR0302 4mg BD0/10 (0%)1/10 (10%)5/10 (50%)
Extension Phase-placebo → SHR0302 4mg QD0/13 (0%)0/13 (0%)5/13 (38.5%)
Most frequent serious events
Most frequent serious events
EventTreatment Phase-SHR0302 8mg QDTreatment Phase-SHR0302 4mg BDTreatment Phase-SHR0302 4mg QDTreatment Phase-PlaceboExtension Phase-SHR0302 8mg QD → SHR0302 8mg QDExtension Phase-SHR0302 4mg BD → SHR0302 4mg BDExtension Phase-SHR0302 4mg QD → SHR0302 4mg QDExtension Phase-placebo → SHR0302 8mg QDExtension Phase-placebo → SHR0302 4mg BDExtension Phase-placebo → SHR0302 4mg QD
Colitis ulcerativeGastrointestinal disorders1/410/412/411/411/360/390/351/111/100/13
Anal abscessInfections and infestations0/410/410/411/410/360/390/350/110/100/13
Cytomegalovirus infectionInfections and infestations1/410/410/410/410/360/390/350/110/100/13
Liver abscessInfections and infestations0/410/410/411/410/360/390/350/110/100/13
SynovitisMusculoskeletal and connective tissue disorders1/410/410/410/410/360/390/350/110/100/13
Most frequent other events
Showing 10 of 34
Most frequent other events
EventTreatment Phase-SHR0302 8mg QDTreatment Phase-SHR0302 4mg BDTreatment Phase-SHR0302 4mg QDTreatment Phase-PlaceboExtension Phase-SHR0302 8mg QD → SHR0302 8mg QDExtension Phase-SHR0302 4mg BD → SHR0302 4mg BDExtension Phase-SHR0302 4mg QD → SHR0302 4mg QDExtension Phase-placebo → SHR0302 8mg QDExtension Phase-placebo → SHR0302 4mg BDExtension Phase-placebo → SHR0302 4mg QD
AnaemiaBlood and lymphatic system disorders1/415/411/411/410/362/391/350/112/100/13
White blood cell count decreasedInvestigations2/410/411/410/414/360/391/350/111/100/13
LeukocytosisBlood and lymphatic system disorders0/411/411/410/410/360/390/350/111/100/13
Sinus bradycardiaCardiac disorders0/410/410/410/411/360/390/350/111/100/13
FolliculitisInfections and infestations0/410/410/410/411/361/390/350/111/100/13
Gastrointestinal infectionInfections and infestations0/410/410/410/411/360/390/350/111/100/13
InfluenzaInfections and infestations0/410/410/410/410/360/390/350/111/100/13
Alanine aminotransferase increasedInvestigations1/410/412/411/410/360/391/351/111/100/13
Bilirubin conjugated increasedInvestigations0/410/410/410/411/360/390/350/111/100/13
Blood bilirubin increasedInvestigations0/410/410/410/412/360/390/350/111/100/13

Baseline characteristics

Age, Continuous
Age, Continuous(years)SHR0302 8mg QDSHR0302 4mg BDSHR0302 4mg QDPlaceboTotal
Mean39.6 ± 13.340.3 ± 12.339.6 ± 10.042.7 ± 12.940.5 ± 12.2
Sex: Female, Male
Sex: Female, Male(Participants)SHR0302 8mg QDSHR0302 4mg BDSHR0302 4mg QDPlaceboTotal
Female1415132264
Male27262819100
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SHR0302 8mg QDSHR0302 4mg BDSHR0302 4mg QDPlaceboTotal
American Indian or Alaska Native00000
Asian29252524103
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White1216161761
More than one race00000
Unknown or Not Reported00000
Time since initial primary diagnosis
Time since initial primary diagnosis(years)SHR0302 8mg QDSHR0302 4mg BDSHR0302 4mg QDPlaceboTotal
Mean5.05 ± 4.165.62 ± 5.625.17 ± 5.175.77 ± 5.195.40 ± 5.03
08

Study locations

67 sites
  • Wellness Clinical Research, LLLC-Central Florida
    Lake Wales, Florida 33853, United States
  • West Central Gastroenterology d/b/a Gastro Florida
    Tampa, Florida 33626, United States
  • Digestive Disease Specialists, Inc.
    Oklahoma City, Oklahoma 73112, United States
  • Guangdong Provincial People's Hospital
    Guangzhou, Guangdong 510000, China
  • The First Affiliated Hospital, Sun Yat-sen University
    Guangzhou, Guangdong 510080, China
  • Henan Provincial People's Hospital
    Zhengzhou, Henan 453000, China
  • Baotou Central Hospital
    Baotou, Inner Mongalia 014040, China
  • Liaocheng People's Hospital
    Liaocheng, Shandong 252000, China
  • Peking University Shougang Hospital
    Beijing, 100041, China
  • Peking University Third Hospital
    Beijing, 100191, China
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, 233004, China
  • The First Hospital of Jillin University
    Changchun, 130021, China
  • Xiangya Hospital Central South University
    Changsha, 410008, China
  • West China Hospital Sichuan University
    Chengdu, 610041, China
  • Fujian Provincial Hospital
    Fuzhou, 350001, China
  • The Sixth Affiliated Hospital of Sun Yat- Sen University
    Guangzhou, 510655, China
  • Sir Run Run Shaw Hospital
    Hangzhou, 310016, China
  • Huaian First People's Hospital
    Huai'an, 223300, China
  • Huzhou Central Hospital
    Huzhou, 313000, China
  • Qilu Hospital of Shandong University
    Jinan, 250012, China
  • The First People's Hospital of Lianyungang
    Lianyungang, 222061, China
  • Jiangsu Province Hospital
    Nanjing, 210006, China
  • Nanjing First Hospital
    Nanjing, 210006, China
  • Nanjing Drum Tower Hospital
    Nanjing, 210008, China
  • Zhongda Hospital Southeast University
    Nanjing, 210009, China
  • Pingxiang People's Hospital
    Pingxiang, 337000, China
  • Shanghai East Hospital
    Shanghai, 200000, China
  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine
    Shanghai, 200025, China
  • Renji Hospital, Shanghai Jiaotong University School of Medicine
    Shanghai, 200127, China
  • The First Hospital of China Medical University
    Shenyang, 110001, China
  • The University of Hong Kong - Shenzhen Hospital
    Shenzhen, 518000, China
  • Shanxi Provincial People's Hospital
    Taiyuan, 030001, China
  • Second Hospital of Shanxi Medical University
    Taiyuan, 030012, China
  • Tianjin Union Medical Center
    Tianjin, 300000, China
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, 325000, China
  • Tongji Hospital Affiliated to Tongji Medicine College
    Wuhan, 430030, China
  • Renmin Hospital of Wuhan University
    Wuhan, 430060, China
  • Yijishan Hospital of Wannan Medical College
    Wuhu, 241001, China
  • Indywidualma Specjalistyczna Praktyka Lekarska Maciej Zymla
    Knurów, 44-190, Poland
  • NZOZ Almedica
    Nowy Targ, 34400, Poland
  • SOLUMED Centrum Medyczne
    Poznań, 60-529, Poland
  • KO-MED Centra Kliniczne Plulawy
    Puławy, 24-100, Poland
  • Specjalistyczna Praktyka Lekarska dr med. Marek Horynski
    Sopot, 81-756, Poland
  • KO-MED Centra Kliniczne Staszow
    Staszów, 28-200, Poland
  • Twoja Przychodnia-Szczecinskie Centrum Medyczne
    Szczecin, 71434, Poland
  • Nzoz Formed
    Wadowice, 01868, Poland
  • Nzoz Formed
    Wadowice, 34100, Poland
  • Nzoz Vivamed
    Warszawa, 03-580, Poland
  • PlanetMed sp. z o.o.
    Wrocław, 53-333, Poland
  • Amicare Sp. z o.o. Sp.k
    Łódź, 90-644, Poland
  • IP Clinic
    Łódź, 90752, Poland
  • Wellness Clinical Research, LLC
    Vega Baja, 00694, Puerto Rico
  • RCI Chernivtsi Regional Clinical Hospital Dept of Gastroenterology Bukovinsky SMU
    Chernivtsi, 58002, Ukraine
  • I.I.Mechnykov Dnipropetrovsk Regional Clinical Hospital
    Dnipro, 49005, Ukraine
  • Central City Clinical Hospital Dept of Theraphy No. 2 SHEI Ivano-Frankivsk NMU
    Ivano-Frankivs'k, 76018, Ukraine
  • Ivana -Frankivsk Hospital
    Ivano-Frankivs'k, 76018, Ukraine
  • CHI Kharkiv City Clinical Hospital #13
    Kharkiv, 61124, Ukraine
  • CI Karabelesh Kherson CCH
    Kherson, 73000, Ukraine
  • Kherson City Clinical Hospital
    Kherson, 73000, Ukraine
  • Khmelnytska Regional Hospital
    Khmelnytskyi, 29000, Ukraine
  • Kyiv City Clinical Hospital #1
    Kyiv, 02091, Ukraine
  • Kyiv Railway Clinical Hospital #2 of Branch "Health Center" of the Public Joint Stock Company "Ukrai
    Kyiv, 03049, Ukraine
  • CNE of Lviv Regional Council Lviv Regional Clinical Hospital
    Lviv, 79010, Ukraine
  • Vinnytsia M.I.Pyrogov Regional Clinical Hospital
    Vinnytsia, 21018, Ukraine
  • CCH #1 Vinnytsia M.I. Pyrogov NMU Ch of Propaedeutics of IM
    Vinnytsia, 21029, Ukraine
  • CI City Clinical Hospital #6 Dept of Gastroenterology
    Zaporizhzhia, 69035, Ukraine
  • O.F. Herbachevskiyi Zhytomyr Regional Clinical Hospital
    Zhytomyr, 10002, Ukraine
09

References and documents

Publications

  • Chen B, Zhong J, Li X, Pan F, Ding Y, Zhang Y, Chen H, Liu F, Zhang Z, Zhang L, Drozda R, Oliinyk O, Goh AH, Chen X, Sun X, Rubin DT, Sandborn WJ, Chen M. Efficacy and Safety of Ivarmacitinib in Patients With Moderate-to-Severe, Active, Ulcerative Colitis: A Phase II Study. Gastroenterology. 2022 Dec;163(6):1555-1568. doi: 10.1053/j.gastro.2022.08.007. Epub 2022 Aug 10. PubMed 35963369 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Nov 2020, 19 months.

Results were first posted in Nov 2022, 1 year 11 months after primary completion.

Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 19 months is below that.

Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2018
First posted
Sep 18, 2018
StartActual
Apr 13, 2019
Primary completionActual
Nov 30, 2020
CompletionActual
Feb 3, 2021
Results first posted
Nov 22, 2022
Last update
Jun 2, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03675477
Responsible party
Sponsor
First posted
Sep 18, 2018
Start date
Apr 13, 2019
Primary completion
Nov 30, 2020
Completion
Feb 3, 2021
Results posted
Nov 22, 2022
Last update
Jun 2, 2023

Study contacts

Xiang Chen
study director · Reistone Pharma

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivarmacitinib

Start the discussion